1. Volume 142, Issue 5, Pages 1132-1139.e1 (May 2012)
Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon 
Josh Levitsky, Maria Isabel Fiel, John P. Norvell, Edward Wang, Kymberly D. Watt, Michael P. Curry, Sumeet Tewani, Timothy M. McCashland, Maarouf A. Hoteit, Abraham Shaked, Samuel Saab, Amanda C. Chi, Amy Tien, Thomas D. Schiano 
Gastroenterology 
Volume 142, Issue 5, Pages e1 (May 2012)
DOI: /j.gastro
Copyright © 2012 AGA Institute Terms and Conditions

2. Figure 1
Kaplan–Meier analyses of patient/graft survival (IGD patients vs non-IGD controls). (A) Overall patient survival; (B) overall graft survival; (C) patient survival by SVR; (D) graft survival by SVR.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions

3. Figure 2
Case examples of PEG-IGD. (A) Pre-PEG therapy recurrent hepatitis C and mild plasma cell infiltration: portal inflammation with increase in plasma cells (arrows, score of 2); (B) IGD: plasma cell hepatitis (arrows, score of 3) after 3 months of PEG; (C) pre-PEG therapy recurrent hepatitis C with dense lymphocytic infiltrate, mild interface hepatitis; surrounding parenchyma shows foci of necroinflammation. (D) IGD: acute cellular rejection 2 months after PEG: portal tract with heavy infiltrate of inflammatory cells consisting of lymphocytes and eosinophils, endotheliitis, and bile duct damage (Rejection Activity Index = 7); (E) pre-PEG therapy recurrent hepatitis C: portal inflammation and interface hepatitis (no plasma cells or evidence of rejection); (F) IGD: ductopenic chronic rejection after 2 months of PEG: 2 portal tracts displaying absence of bile ducts; seen in 7 of 10 portal triads. (A, B) H&E, original magnification 100×. (C, D) H&E, original magnification 200×. (E, F) H&E, original magnification 40×.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2012 AGA Institute Terms and Conditions